Hospital
The New York and Presbyterian Hospital
The New York and Presbyterian Hospital was paid $18.84M by Medicaid between Apr 2018 and Dec 2024, across 269 billing codes. Its largest line is 99283, emergency room visit (moderate) — 11% of everything it billed.
33Billing provider infoTHE NEW YORK AND PRESBYTERIAN HOSPITAL
BRONXVILLE, NY 10708
BRONXVILLE, NY 10708
33aNPI1780196345assigned 11/03/2017
33bProvider typeGeneral Acute Care Hospital
28Total paid$18.84M
24GClaims445,410
24DCodes billed269
24AFirst – last monthApr 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in New York
Rank by total paid#63 of 231
Median peer was paid$561K
This provider vs. median34×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 10,208 | $217K | |
| 2019 | 44,499 | $1.06M | |
| 2020 | 87,641 | $2.13M | |
| 2021 | 84,508 | $2.95M | |
| 2022 | 72,315 | $3.97M | |
| 2023 | 81,473 | $4.79M | |
| 2024incomplete | 64,766 | $3.73M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 11% | 11,921 | 11,334 | $2.04M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 10% | 11,939 | 11,590 | $1.94M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 10% | 12,104 | 11,609 | $1.89M |
| 96361 | Intravenous infusion, hydration; each additional hour | 9.2% | 6,894 | 6,162 | $1.74M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 4.7% | 8,977 | 2,368 | $879K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.9% | 2,591 | 2,554 | $741K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | 3.8% | 1,051 | 1,008 | $709K |
| 70450 | Computed tomography, head or brain; without contrast material | 3.7% | 2,456 | 2,415 | $691K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | 3.3% | 686 | 683 | $630K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 2.8% | 813 | 808 | $529K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 2.8% | 6,887 | 6,579 | $520K |
| 80053 | Comprehensive metabolic panel | 2.6% | 25,385 | 23,288 | $491K |
257 more codes
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.0% | 2,209 | $377K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.7% | 2,750 | $326K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.7% | 2,012 | $318K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 1.5% | 4,618 | $275K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 1.1% | 5,975 | $204K |
| 99214 | Doctor's office visit, returning patient (more involved) | 1.0% | 1,124 | $189K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 2,658 | $185K |
| 97161 | <1% | 1,094 | $145K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 735 | $145K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 503 | $143K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 912 | $142K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 4,210 | $134K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 5,286 | $122K |
| 86850 | <1% | 3,430 | $114K | |
| 87486 | <1% | 2,689 | $102K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 6,279 | $100K |
| 86901 | <1% | 4,414 | $100K | |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 459 | $98K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 364 | $98K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 4,403 | $86K |
| 86900 | <1% | 4,455 | $85K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,818 | $77K |
| 80076 | <1% | 3,208 | $70K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 6,992 | $57K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 353 | $56K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 61 | $55K |
| 76830 | Ultrasound, transvaginal | <1% | 1,520 | $55K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 5,234 | $54K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,979 | $53K |
| 87581 | <1% | 2,689 | $52K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 2,693 | $52K |
| 83880 | <1% | 1,616 | $51K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 5,077 | $50K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 3,108 | $50K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,284 | $49K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 314 | $49K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 7,329 | $47K |
| 84702 | <1% | 4,649 | $46K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,928 | $45K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 25,899 | $45K |
| 87631 | <1% | 719 | $44K | |
| 81401 | <1% | 208 | $44K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 1,148 | $41K |
| 82607 | <1% | 3,260 | $40K | |
| 80061 | Lipid panel | <1% | 6,322 | $39K |
| 84439 | <1% | 5,159 | $37K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 930 | $36K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,111 | $35K |
| 59025 | Fetal non-stress test | <1% | 138 | $34K |
| 82746 | <1% | 2,708 | $33K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 5,411 | $31K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 1,436 | $31K |
| 86328 | <1% | 741 | $30K | |
| 87480 | <1% | 1,976 | $29K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 5,789 | $28K |
| J3490 | Unclassified drugs | <1% | 235 | $28K |
| 88307 | <1% | 581 | $27K | |
| 81025 | <1% | 7,151 | $26K | |
| 87660 | <1% | 2,057 | $25K | |
| 87510 | <1% | 1,913 | $23K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 1,422 | $23K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 342 | $23K |
| 87340 | <1% | 2,325 | $22K | |
| 82728 | <1% | 1,721 | $22K | |
| 85610 | <1% | 7,323 | $22K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 996 | $22K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 36 | $21K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 4,479 | $20K |
| 86803 | <1% | 1,977 | $20K | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 334 | $20K |
| 86592 | <1% | 3,224 | $19K | |
| 81243 | <1% | 382 | $18K | |
| 84484 | <1% | 5,498 | $18K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 128 | $18K |
| 85380 | <1% | 615 | $16K | |
| 97116 | <1% | 440 | $16K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 331 | $16K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 459 | $15K |
| 86694 | <1% | 479 | $15K | |
| 85730 | <1% | 6,177 | $14K | |
| 76801 | <1% | 310 | $14K | |
| 84152 | <1% | 596 | $13K | |
| 81001 | <1% | 8,521 | $13K | |
| 86618 | <1% | 360 | $12K | |
| 86762 | <1% | 772 | $12K | |
| 84146 | <1% | 546 | $12K | |
| 83001 | <1% | 564 | $11K | |
| 81329 | <1% | 117 | $11K | |
| 83021 | <1% | 582 | $11K | |
| 82803 | <1% | 308 | $11K | |
| 83540 | <1% | 2,283 | $11K | |
| 83550 | <1% | 2,268 | $11K | |
| 86765 | <1% | 777 | $10K | |
| 88342 | <1% | 127 | $10K | |
| 76376 | <1% | 1,335 | $9K | |
| 84403 | <1% | 310 | $9K | |
| 83020 | <1% | 580 | $8K | |
| 85027 | <1% | 3,072 | $8K | |
| 83605 | <1% | 1,384 | $8K | |
| 83002 | <1% | 404 | $8K | |
| 71045 | Radiologic examination, chest; single view | <1% | 2,343 | $8K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 5,217 | $7K |
| 82670 | <1% | 236 | $7K | |
| 93971 | <1% | 189 | $7K | |
| 83735 | <1% | 2,786 | $7K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,552 | $7K |
| 83690 | <1% | 5,124 | $7K | |
| 81003 | <1% | 4,515 | $7K | |
| 76813 | <1% | 334 | $6K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 40 | $6K |
| 88312 | <1% | 598 | $6K | |
| 82150 | <1% | 1,237 | $6K | |
| 86140 | <1% | 1,783 | $6K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 117 | $6K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 3,860 | $6K |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 24 | $6K |
| 87150 | <1% | 73 | $5K | |
| 76942 | <1% | 56 | $5K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 6,265 | $5K |
| 86480 | <1% | 106 | $5K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 13 | $5K |
| 86706 | <1% | 480 | $5K | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 100 | $5K |
| 82550 | <1% | 1,212 | $4K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 12 | $4K |
| 84402 | <1% | 161 | $4K | |
| 36416 | <1% | 198 | $4K | |
| 76641 | <1% | 151 | $4K | |
| 82947 | <1% | 568 | $4K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 2,570 | $4K |
| 90715 | <1% | 144 | $4K | |
| G0399 | Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | <1% | 30 | $4K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 21 | $4K |
| 95806 | <1% | 12 | $4K | |
| 86704 | <1% | 335 | $4K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 27 | $3K |
| 83525 | <1% | 243 | $3K | |
| 86703 | <1% | 216 | $3K | |
| 82950 | <1% | 604 | $3K | |
| C9290 | Injection, bupivacaine liposome, 1 mg | <1% | 15 | $3K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 13 | $3K |
| 85651 | <1% | 1,135 | $3K | |
| 83655 | <1% | 165 | $2K | |
| 99205 | Prolong outpt/office vis | <1% | 14 | $2K |
| 84145 | <1% | 233 | $2K | |
| 93000 | <1% | 2,019 | $2K | |
| 87081 | <1% | 434 | $2K | |
| 87070 | <1% | 653 | $2K | |
| 87088 | <1% | 310 | $2K | |
| 80320 | <1% | 620 | $2K | |
| 76000 | <1% | 40 | $2K | |
| 87186 | <1% | 558 | $2K | |
| 82248 | <1% | 293 | $2K | |
| 85007 | <1% | 1,244 | $2K | |
| 85055 | <1% | 49 | $2K | |
| 73610 | <1% | 193 | $2K | |
| 82043 | <1% | 344 | $2K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 3,885 | $2K |
| 73630 | <1% | 219 | $2K | |
| 82962 | <1% | 1,938 | $1K | |
| 87430 | <1% | 339 | $1K | |
| 96376 | <1% | 453 | $1K | |
| 84100 | <1% | 797 | $1K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 32 | $1K |
| 84550 | <1% | 297 | $1K | |
| 85379 | <1% | 1,213 | $1K | |
| 83970 | <1% | 28 | $1K | |
| J2704 | Injection, propofol, 10 mg | <1% | 4,215 | $1K |
| 86376 | <1% | 73 | $1K | |
| 86431 | <1% | 206 | $1K | |
| 82948 | <1% | 609 | $1K | |
| 86756 | <1% | 134 | $1K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 115 | $1K |
| 72100 | <1% | 139 | $1K | |
| 73030 | <1% | 199 | $971.90 | |
| 86038 | <1% | 185 | $952.92 | |
| 84153 | <1% | 49 | $920.17 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 533 | $904.37 |
| 86039 | <1% | 177 | $903.46 | |
| 97165 | <1% | 13 | $877.66 | |
| 86735 | <1% | 109 | $864.74 | |
| 82977 | <1% | 172 | $837.56 | |
| 77080 | <1% | 12 | $815.00 | |
| 86800 | <1% | 60 | $802.85 | |
| 88304 | <1% | 41 | $777.70 | |
| 86696 | <1% | 54 | $767.08 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 680 | $749.12 |
| 86787 | <1% | 94 | $737.66 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,592 | $674.91 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 4,848 | $664.86 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,833 | $640.33 |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 242 | $633.09 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 161 | $605.80 |
| 82784 | <1% | 33 | $578.66 | |
| 76536 | <1% | 26 | $570.00 | |
| 86665 | <1% | 12 | $566.00 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 906 | $560.91 |
| 73560 | <1% | 115 | $542.70 | |
| 82627 | <1% | 25 | $527.61 | |
| J3410 | Injection, hydroxyzine hcl, up to 25 mg | <1% | 116 | $516.34 |
| 84481 | <1% | 49 | $441.58 | |
| 83615 | <1% | 148 | $421.57 | |
| 87040 | <1% | 294 | $368.80 | |
| 82570 | <1% | 48 | $349.94 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 6,148 | $336.21 |
| 84155 | <1% | 135 | $313.94 | |
| 84436 | <1% | 85 | $306.55 | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 289 | $303.71 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 679 | $291.53 |
| 85652 | <1% | 416 | $272.01 | |
| 84480 | <1% | 54 | $269.05 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 928 | $244.39 |
| 76642 | <1% | 13 | $219.97 | |
| 82533 | <1% | 12 | $211.90 | |
| 86235 | <1% | 13 | $201.82 | |
| 86695 | <1% | 30 | $196.91 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,423 | $146.21 |
| 85045 | <1% | 55 | $143.80 | |
| 86708 | <1% | 15 | $136.50 | |
| 84479 | <1% | 53 | $124.76 | |
| 86308 | <1% | 18 | $118.00 | |
| 86709 | <1% | 12 | $111.50 | |
| 87147 | <1% | 47 | $105.08 | |
| 82553 | <1% | 24 | $99.14 | |
| 82105 | <1% | 14 | $93.46 | |
| 87205 | <1% | 50 | $87.23 | |
| 82270 | <1% | 28 | $76.66 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,522 | $65.59 |
| 73130 | <1% | 26 | $50.26 | |
| 80179 | <1% | 53 | $41.64 | |
| C1769 | Guide wire | <1% | 28 | $39.74 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 114 | $32.90 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 519 | $31.33 |
| G1003 | Clinical decision support mechanism medicalis, as defined by the medicare appropriate use criteria program | <1% | 1,233 | $30.22 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 147 | $29.97 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 354 | $27.98 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 807 | $24.22 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 741 | $23.21 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 111 | $19.23 |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 517 | $6.30 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 112 | $3.58 |
| 80329 | <1% | 13 | $2.24 | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 14 | $2.04 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 609 | $1.39 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 116 | $1.26 |
| J7644 | Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram | <1% | 292 | $0.80 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 110 | $0.00 |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 0% | 14 | $0.00 |
| 80050 | General health panel | 0% | 514 | $0.00 |
| Q9963 | High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml | 0% | 13 | $0.00 |
| 99080 | 0% | 1,444 | $0.00 | |
| C9153 | Injection, amisulpride, 1 mg | 0% | 20 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 12 | $0.00 |
| 76857 | 0% | 13 | $0.00 | |
| J0184 | Injection, amisulpride, 1 mg | 0% | 12 | $0.00 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 12 | $0.00 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | 0% | 44 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialFARRELL, WILLIAM (SENIOR VICE PRESIDENT, FINANCE)
| Provider | Location | Paid |
|---|---|---|
| Hudson Valley Hospital Center | Cortlandt Manor, NY | $15.87M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.